-
1
-
-
68949106269
-
Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite
-
Mueller I, Galinski MR, Baird JK, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009; 9 (9): 555-566.
-
(2009)
Lancet Infect Dis
, vol.9
, Issue.9
, pp. 555-566
-
-
Mueller, I.1
Galinski, M.R.2
Baird, J.K.3
-
2
-
-
40049109886
-
Vivax malaria: Neglected and not benign
-
Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM,. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007; 77 (6 Suppl): 79-87.
-
(2007)
Am J Trop Med Hyg
, vol.77
, Issue.6 SUPPL.
, pp. 79-87
-
-
Price, R.N.1
Tjitra, E.2
Guerra, C.A.3
Yeung, S.4
White, N.J.5
Anstey, N.M.6
-
3
-
-
84870381414
-
The global public health significance of Plasmodium vivax
-
Battle KE, Gething PW, Elyazar IR, et al. The global public health significance of Plasmodium vivax. Adv Parasitol. 2012; 80: 1-111.
-
(2012)
Adv Parasitol
, vol.80
, pp. 1-111
-
-
Battle, K.E.1
Gething, P.W.2
Elyazar, I.R.3
-
4
-
-
84866360184
-
A long neglected world malaria map: Plasmodium vivax endemicity in 2010
-
Gething PW, Elyazar IR, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012; 6 (9): e1814.
-
(2012)
PLoS Negl Trop Dis
, vol.6
, Issue.9
-
-
Gething, P.W.1
Elyazar, I.R.2
Moyes, C.L.3
-
5
-
-
80053624564
-
Determinants of relapse periodicity in Plasmodium vivax malaria
-
White NJ,. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011; 10: 297.
-
(2011)
Malar J
, vol.10
, pp. 297
-
-
White, N.J.1
-
7
-
-
84905488233
-
-
WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition. World Health Organization. Accessed 2nd February
-
World Health Organization,. WHO Model Prescribing Information: Drugs Used in Parasitic Diseases-Second Edition. World Health Organization. Available at: http://apps.who.int/medicinedocs/en/d/Jh2922e/ Accessed 2nd February, 2013.
-
(2013)
-
-
-
8
-
-
84865054334
-
Primaquine radical cure of Plasmodium vivax: A critical review of the literature
-
John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012; 11: 280.
-
(2012)
Malar J
, vol.11
, pp. 280
-
-
John, G.K.1
Douglas, N.M.2
Von Seidlein, L.3
-
9
-
-
77958595486
-
Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border
-
Takeuchi R, Lawpoolsri S, Imwong M, et al. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J. 2012; 9: 308.
-
(2012)
Malar J
, vol.9
, pp. 308
-
-
Takeuchi, R.1
Lawpoolsri, S.2
Imwong, M.3
-
10
-
-
79960850180
-
Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)
-
Dow GS, Gettayacamin M, Hansukjariya P, et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J. 2011; 10: 212.
-
(2011)
Malar J
, vol.10
, pp. 212
-
-
Dow, G.S.1
Gettayacamin, M.2
Hansukjariya, P.3
-
11
-
-
33748694158
-
In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti
-
Pradines B, Mamfoumbi MM, Tall A, et al. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother. 2006; 50 (9): 3225-3226.
-
(2006)
Antimicrob Agents Chemother
, vol.50
, Issue.9
, pp. 3225-3226
-
-
Pradines, B.1
Mamfoumbi, M.M.2
Tall, A.3
-
12
-
-
0036655645
-
In vitro activity of tafenoquine alone and in combination with artemisinin against Plasmodium falciparum
-
Ramharter M, Noedl H, Thimasarn K, Wiedermann G, Wernsdorfer G, Wernsdorfer WH,. In vitro activity of tafenoquine alone and in combination with artemisinin against Plasmodium falciparum. Am J Trop Med Hyg. 2002; 67 (1): 39-43.
-
(2002)
Am J Trop Med Hyg
, vol.67
, Issue.1
, pp. 39-43
-
-
Ramharter, M.1
Noedl, H.2
Thimasarn, K.3
Wiedermann, G.4
Wernsdorfer, G.5
Wernsdorfer, W.H.6
-
13
-
-
0026510461
-
Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoes
-
Coleman RE, Clavin AM, Milhous WK,. Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoes. Am J Trop Med Hyg. 1992; 46 (2): 169-182.
-
(1992)
Am J Trop Med Hyg
, vol.46
, Issue.2
, pp. 169-182
-
-
Coleman, R.E.1
Clavin, A.M.2
Milhous, W.K.3
-
14
-
-
34547626830
-
Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects
-
Charles BG, Miller AK, Nasveld PE, Reid MG, Harris IE, Edstein MD,. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob Agents Chemother. 2007; 51 (8): 2709-2715.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, Issue.8
, pp. 2709-2715
-
-
Charles, B.G.1
Miller, A.K.2
Nasveld, P.E.3
Reid, M.G.4
Harris, I.E.5
Edstein, M.D.6
-
15
-
-
0035678895
-
Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers
-
Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG,. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. Br J Clin Pharmacol. 2001; 52 (6): 663-670.
-
(2001)
Br J Clin Pharmacol
, vol.52
, Issue.6
, pp. 663-670
-
-
Edstein, M.D.1
Kocisko, D.A.2
Brewer, T.G.3
Walsh, D.S.4
Eamsila, C.5
Charles, B.G.6
-
16
-
-
0033383602
-
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand
-
Walsh DS, Looareesuwan S, Wilairatana P, et al. Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis. 1999; 180 (4): 1282-1287.
-
(1999)
J Infect Dis
, vol.180
, Issue.4
, pp. 1282-1287
-
-
Walsh, D.S.1
Looareesuwan, S.2
Wilairatana, P.3
-
17
-
-
19944433208
-
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse
-
Walsh DS, Wilairatana P, Tang DB, et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis. 2004; 39 (8): 1095-1103.
-
(2004)
Clin Infect Dis
, vol.39
, Issue.8
, pp. 1095-1103
-
-
Walsh, D.S.1
Wilairatana, P.2
Tang, D.B.3
-
18
-
-
84896492260
-
A clinical summary of investigations to determine the haemolytic potential of tafenoquine in G6PD-deficient subjects
-
Washington, DC.
-
Green J, Harrell E, Narayan S, et al. A clinical summary of investigations to determine the haemolytic potential of tafenoquine in G6PD-deficient subjects. Presented at: 62nd Annual Meeting of the American Society of Tropical Medicine and Hygiene, 2013, Washington, DC.
-
(2013)
Presented At: 62nd Annual Meeting of the American Society of Tropical Medicine and Hygiene
-
-
Green, J.1
Harrell, E.2
Narayan, S.3
-
19
-
-
84896489887
-
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): A multicentre, double-blind, randomised, phase 2b dose-selection study
-
Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2013; 383 (9922): 1049-1058.
-
(2013)
Lancet
, vol.383
, Issue.9922
, pp. 1049-1058
-
-
Llanos-Cuentas, A.1
Lacerda, M.V.2
Rueangweerayut, R.3
-
20
-
-
34447568519
-
Cardiotoxicity of antimalarial drugs
-
White NJ,. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007; 7 (8): 549-558.
-
(2007)
Lancet Infect Dis
, vol.7
, Issue.8
, pp. 549-558
-
-
White, N.J.1
-
21
-
-
0036656069
-
The effects of antimalarial drugs on ventricular repolarization
-
Touze JE, Heno P, Fourcade L, et al. The effects of antimalarial drugs on ventricular repolarization. Am J Trop Med Hyg. 2002; 67 (1): 54-60.
-
(2002)
Am J Trop Med Hyg
, vol.67
, Issue.1
, pp. 54-60
-
-
Touze, J.E.1
Heno, P.2
Fourcade, L.3
-
22
-
-
0022555299
-
Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care
-
Roden DM, Woosley RL, Primm RK,. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986; 111 (6): 1088-1093.
-
(1986)
Am Heart J
, vol.111
, Issue.6
, pp. 1088-1093
-
-
Roden, D.M.1
Woosley, R.L.2
Primm, R.K.3
-
23
-
-
84875040964
-
Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement
-
Vereckei A, Fazakas A, Balo T, Fekete B, Molnar MJ, Karadi I,. Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement. Immunopharmacol Immunotoxicol. 2013; 35 (2): 304-306.
-
(2013)
Immunopharmacol Immunotoxicol
, vol.35
, Issue.2
, pp. 304-306
-
-
Vereckei, A.1
Fazakas, A.2
Balo, T.3
Fekete, B.4
Molnar, M.J.5
Karadi, I.6
-
24
-
-
77949752659
-
Arrhythmias in systemic lupus erythematosus
-
Teixeira RA, Borba EF, Bonfa E, Martinelli Filho M,. Arrhythmias in systemic lupus erythematosus. Rev Bras Reumatol. 2010; 50 (1): 81-89.
-
(2010)
Rev Bras Reumatol
, vol.50
, Issue.1
, pp. 81-89
-
-
Teixeira, R.A.1
Borba, E.F.2
Bonfa, E.3
Martinelli Filho, M.4
-
25
-
-
84905488230
-
-
version 8, November 2010. Document on file: GM2007/00152/04 Glaxosmithkline
-
GlaxoSmithKline,. Clinical Investigator's Brochure for SB252263, version 8, November 2010. Document on file: GM2007/00152/04.
-
Clinical Investigator's Brochure for SB252263
-
-
-
26
-
-
84888042382
-
Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects
-
Miller A, Harrell E, Ye L, et al. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol. 2013; 76 (6): 858-867.
-
(2013)
Br J Clin Pharmacol
, vol.76
, Issue.6
, pp. 858-867
-
-
Miller, A.1
Harrell, E.2
Ye, L.3
-
27
-
-
84905488231
-
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
-
The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs. E14, Step 5 Accessed 24th February, 2013
-
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs. E14, Step 5. ICH Steering Committee. Available at: http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf Accessed 24th February, 2013.
-
ICH Steering Committee
-
-
-
28
-
-
0031836936
-
First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial
-
Brueckner RP, Lasseter KC, Lin ET, Schuster BG,. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg. 1998; 58 (5): 645-649.
-
(1998)
Am J Trop Med Hyg
, vol.58
, Issue.5
, pp. 645-649
-
-
Brueckner, R.P.1
Lasseter, K.C.2
Lin, E.T.3
Schuster, B.G.4
-
29
-
-
84862270599
-
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
-
del Corral A, Dutreix C, Huntsman-Labed A, et al. Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Cancer Chemother Pharmacol. 2012; 69 (5): 1255-1263.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, Issue.5
, pp. 1255-1263
-
-
Del Corral, A.1
Dutreix, C.2
Huntsman-Labed, A.3
-
30
-
-
79960602475
-
Population pharmacokinetic and concentration-QTc models for moxifloxacin: Pooled analysis of 20 thorough QT studies
-
Florian JA, Tornoe CW, Brundage R, Parekh A, Garnett CE,. Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol. 2011; 51 (8): 1152-1162.
-
(2011)
J Clin Pharmacol
, vol.51
, Issue.8
, pp. 1152-1162
-
-
Florian, J.A.1
Tornoe, C.W.2
Brundage, R.3
Parekh, A.4
Garnett, C.E.5
-
31
-
-
79958806529
-
Creation of a knowledge management system for QT analyses
-
Tornoe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu JV,. Creation of a knowledge management system for QT analyses. J Clin Pharmacol. 2011; 51 (7): 1035-1042.
-
(2011)
J Clin Pharmacol
, vol.51
, Issue.7
, pp. 1035-1042
-
-
Tornoe, C.W.1
Garnett, C.E.2
Wang, Y.3
Florian, J.4
Li, M.5
Gobburu, J.V.6
-
32
-
-
84891088773
-
Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects
-
Taubel J, Ferber G, Lorch U, Batchvarov V, Savelieva I, Camm AJ,. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Br J Clin Pharmacol. 2014; 77 (1): 170-179.
-
(2014)
Br J Clin Pharmacol
, vol.77
, Issue.1
, pp. 170-179
-
-
Taubel, J.1
Ferber, G.2
Lorch, U.3
Batchvarov, V.4
Savelieva, I.5
Camm, A.J.6
-
33
-
-
0035071699
-
Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers
-
Lettieri J, Vargas R, Agarwal V, Liu P,. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet. 2001; 40 (Suppl 1): 19-25.
-
(2001)
Clin Pharmacokinet
, vol.40
, Issue.SUPPL. 1
, pp. 19-25
-
-
Lettieri, J.1
Vargas, R.2
Agarwal, V.3
Liu, P.4
-
34
-
-
68549115281
-
A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200mg weekly versus placebo for 6 months in healthy volunteers
-
Leary KJ, Riel MA, Roy MJ, et al. A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200mg weekly versus placebo for 6 months in healthy volunteers. Am J Trop Med Hyg. 2009; 81 (2): 356-362.
-
(2009)
Am J Trop Med Hyg
, vol.81
, Issue.2
, pp. 356-362
-
-
Leary, K.J.1
Riel, M.A.2
Roy, M.J.3
-
35
-
-
0034631384
-
Malaria chemoprophylaxis with tafenoquine: A randomised study
-
Lell B, Faucher JF, Missinou MA, et al. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet. 2000; 355 (9220): 2041-2045.
-
(2000)
Lancet
, vol.355
, Issue.9220
, pp. 2041-2045
-
-
Lell, B.1
Faucher, J.F.2
Missinou, M.A.3
-
36
-
-
75749100191
-
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects
-
Nasveld PE, Edstein MD, Reid M, et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010; 54 (2): 792-798.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, Issue.2
, pp. 792-798
-
-
Nasveld, P.E.1
Edstein, M.D.2
Reid, M.3
-
37
-
-
4944234920
-
Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P falciparum malaria
-
Walsh DS, Eamsila C, Sasiprapha T, et al. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. J Infect Dis. 2004; 190 (8): 1456-1463.
-
(2004)
J Infect Dis
, vol.190
, Issue.8
, pp. 1456-1463
-
-
Walsh, D.S.1
Eamsila, C.2
Sasiprapha, T.3
-
38
-
-
0035893187
-
A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria
-
Shanks GD, Oloo AJ, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001; 33 (12): 1968-1974.g
-
(2001)
Clin Infect Dis
, vol.33
, Issue.12
, pp. 1968-1974
-
-
Shanks, G.D.1
Oloo, A.J.2
Aleman, G.M.3
|